These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35003333)

  • 1. Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US.
    Jin R; Mahtani RL; Accortt N; Lawrence T; Sandschafer D; Loaiza-Bonilla A
    Ther Adv Med Oncol; 2021; 13():17588359211041961. PubMed ID: 35003333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer.
    Rhodes W; DeClue RW; Accortt NA; Jin R; Sandschafer D; Wertz D; Patel K
    Future Oncol; 2021 Dec; 17(36):5119-5127. PubMed ID: 34698523
    [No Abstract]   [Full Text] [Related]  

  • 3. Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb).
    Jin R; Ogbomo AS; Accortt NA; Lal LS; Bishi G; Sandschafer D; Goldschmidt JH
    Ther Adv Med Oncol; 2023; 15():17588359231182386. PubMed ID: 37360769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer.
    Pham C; Niu F; Delate T; Buchschacher GL; Li Y; Ekinci E; Le K; Hui RL
    BioDrugs; 2023 Nov; 37(6):891-899. PubMed ID: 37747629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective Indication-Matched Cohort Study of Reference Product and Biosimilar: Bevacizumab Versus Bevacizumab-Awwb.
    Booth JP; Pilz J
    Hosp Pharm; 2022 Aug; 57(4):455-461. PubMed ID: 35898250
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union.
    Wyrwicz L; Rodríguez Sánchez CA; Sánchez-Rovira P; Lewis S; Sandschafer D; San T
    Future Oncol; 2024 Apr; 20(13):821-832. PubMed ID: 38305004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A descriptive analysis of real-world oncology biosimilar use in Japan.
    Roth JA; Rahshenas M; Nowacki G; Masurkar N; Shelbaya A; Tajima K; Dorman S; Ono C
    Future Oncol; 2024; 20(25):1837-1850. PubMed ID: 38864611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database.
    Xue X; Qian J
    Expert Opin Drug Saf; 2024 May; ():1-10. PubMed ID: 38680112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
    Serna-Gallegos TR; La-Fargue CJ; Tewari KS
    Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world use of IBI305, a bevacizumab biosimilar, in a tertiary caner-specialized hospital in China.
    Chen Z; Wang Y; Yang J; Zhou H; Li G
    J Clin Pharm Ther; 2022 Dec; 47(12):2274-2278. PubMed ID: 36418209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
    Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
    Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cost savings of biosimilar and dose rounding utilization in oncology care.
    Abdelmeseh V; Brown BR; Huynh JP; Zullo AR
    J Oncol Pharm Pract; 2023 Sep; 29(6):1437-1442. PubMed ID: 36259235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States.
    Mai X; Mendelsohn AB; Marshall J; Lin ND; McDermott CL; Ko JS; Pawloski PA; Jamal-Allial A; Daniels K; McMahill-Walraven CN; Djibo DA; Lockhart CM
    J Manag Care Spec Pharm; 2024 Oct; 30(10):1160-1166. PubMed ID: 39321121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars as a Future, Promising Solution for Financial Toxicity: A Review with Emphasis on Bevacizumab.
    Saleem T; Qurashi H; Jamali M; Chan Gomez J; Kanderi T
    Cureus; 2020 Jul; 12(7):e9300. PubMed ID: 32832297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World Data.
    Lu B; Dvorani E; Nguyen L; Beca JM; Mercer RE; Adamic A; Muñoz C; Chan KKW
    Value Health; 2024 Dec; 27(12):1689-1697. PubMed ID: 39127249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world usage of bevacizumab-bvzr biosimilar in US oncology practice.
    Yang J; Kelton JM; Thompson J; Alvir JMJ; Maculaitis MC; Shelbaya A
    Am J Manag Care; 2022 Apr; 28(4):160-166. PubMed ID: 35420744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
    Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D
    Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Clinical Review of Biosimilars Approved in Oncology.
    Ngo D; Chen J
    Ann Pharmacother; 2021 Mar; 55(3):362-377. PubMed ID: 32715722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.